Manuel L. Penichet
Affiliations: | Molecular Biology 0573 | University of California, Los Angeles, Los Angeles, CA |
Area:
Cell Biology, Molecular BiologyGoogle:
"Manuel Penichet"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Candelaria PV, Nava M, Daniels-Wells TR, et al. (2023) A Fully Human IgE Specific for CD38 as a Potential Therapy for Multiple Myeloma. Cancers. 15 |
| Daniels-Wells TR, Candelaria PV, Kranz E, et al. (2023) Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma. Cancers. 15 |
| Candelaria PV, Nava M, Martínez-Maza O, et al. (2022) Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication. Journal of Immunotherapy (Hagerstown, Md. : 1997). 45: 227-230 |
| Hickerson BT, Daniels-Wells TR, Payes C, et al. (2022) Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. Nature Communications. 13: 558 |
| Markov SD, Caffrey TC, O' Connell KA, et al. (2021) IgE-based therapeutic combination enhances anti-tumor response in preclinical models of pancreatic cancer. Molecular Cancer Therapeutics |
| Epeldegui M, Martínez LE, Daniels-Wells TR, et al. (2021) Targeting TfR1 with the ch128.1/IgG1 antibody inhibits EBV driven lymphomagenesis in immunosuppressed mice bearing EBV+ human primary B-cells. Molecular Cancer Therapeutics |
| Candelaria PV, Leoh LS, Penichet ML, et al. (2021) Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents. Frontiers in Immunology. 12: 607692 |
| Daniels-Wells TR, Candelaria PV, Kranz E, et al. (2020) Abstract 5655: Efficacy of antibodies targeting TfR1 in xenograft mouse models of AIDS-related non-Hodgkin lymphoma Immunology |
| Candelaria PV, Nava M, Martinez-Maza O, et al. (2020) Abstract 4436: Combination therapy with an antibody specific for transferrin receptor 1 (ch128.1/IgG1) and bortezomib or lenalidomide results in increased survival in an in vivo model of human multiple myeloma Immunology. 80: 4436-4436 |
| Daniels-Wells TR, Candelaria PV, Leoh LS, et al. (2019) An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication. Journal of Immunotherapy (Hagerstown, Md. : 1997) |